Flovagatran
Source Flovagatran at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Flovagatran is an experimental parenteral anticoagulant that directly inhibits thrombin (factor IIa). It has been investigated as a potential agent for the prevention and treatment of venous thromboembolism, aiming to complement or replace existing injectable anticoagulants such as heparin and low‑molecular‑weight heparin.
Mechanism of Action
Flovagatran binds directly to the active site of thrombin (factor IIa), blocking its ability to cleave fibrinogen into fibrin and to activate other coagulation factors. By inhibiting this final step of the clotting cascade, it reduces clot formation without requiring antithrombin as a cofactor.
What the Research Shows
Both 2009 and 2011 review articles list flovagatran sodium among novel direct factor IIa inhibitors under clinical testing. The reviews note that such agents are intended to address limitations of older parenteral anticoagulants, such as the need for routine monitoring or renal clearance concerns. No specific trial outcomes, safety data, or comparative efficacy results for flovagatran are provided in the abstracts; its status is described only as investigational.
Reported Benefits
According to the reviews, flovagatran could offer a direct‑acting, parenteral thrombin inhibitor that may simplify anticoagulation management by avoiding the monitoring required for unfractionated heparin and the renal‑clearance issues of low‑molecular‑weight heparin. Its mechanism may also allow use in patients where existing agents are limited.
Limitations of the Evidence
Evidence for flovagatran is limited to its mention in early‑phase development; no clinical trial data, dosing information, or regulatory status are reported. The abstracts do not provide efficacy or safety results, leaving its therapeutic value and comparative performance unknown. Consequently, its role remains speculative pending further studies.
Safety Considerations
The abstracts do not describe specific adverse effects for flovagatran. As a direct thrombin inhibitor, it would be expected to carry a bleeding risk similar to other agents in this class, but the safety profile has not been characterized in the cited literature. Until clinical data are available, caution is warranted.
How It Is Administered
Flovagatran is described as a parenteral (injectable) compound, likely administered intravenously or subcutaneously, though the precise formulation and dosing regimen are not detailed in the available abstracts.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleModerateGómez-Outes A, et al.2009-01-01T00:00:00.000000Z
- Journal ArticleModerateGómez-Outes A, et al.2011-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of drug is flovagatran?
Flovagatran is an experimental injectable anticoagulant that directly inhibits thrombin (factor IIa), placing it in the class of direct thrombin inhibitors.
How does flovagatran work to prevent clots?
It binds to thrombin’s active site, preventing the conversion of fibrinogen to fibrin and blocking downstream activation of other clotting factors, thereby reducing clot formation.
Is flovagatran approved for clinical use?
No. The cited reviews list flovagatran as a compound under clinical testing, and no approval status is reported in the abstracts.
What are the known safety concerns for flovagatran?
Specific safety data are not provided in the abstracts. As a direct thrombin inhibitor, it would be expected to carry a risk of bleeding, but its full safety profile remains undefined.
How would flovagatran be administered?
It is described as a parenteral agent, meaning it would be given by injection (intravenous or subcutaneous), though exact dosing and formulation are not detailed.
What is Flovagatran?
Flovagatran is an experimental parenteral anticoagulant that directly inhibits thrombin (factor IIa). It has been investigated as a potential agent for the prevention and treatment of venous thromboembolism, aiming to complement or replace existing injectable anticoagulants such as heparin and low‑molecular‑weight heparin.